[144] Natera, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 notice for NTRA: An individual proposes to sell 3,000 shares of Natera common stock through Morgan Stanley Smith Barney LLC with an indicated aggregate market value of $479,968.80 and an approximate sale date of 10/01/2025. The shares to be sold were acquired as restricted stock from the issuer in January 2025 (833 and 2,167 shares on 01/27/2025 and 01/26/2025 respectively). The filing also lists multiple prior open-market sales by the same seller totaling 12,372 shares across July–September 2025 with published gross proceeds on each transaction. The filer attests no undisclosed material adverse information and follows Rule 144 disclosure requirements.

Positive

• Securities were acquired as restricted stock directly from the issuer, which clarifies chain of title and compliance with Rule 144
• Planned sale will be executed through a registered broker (Morgan Stanley Smith Barney LLC), supporting orderly disposition

Negative

• Seller completed multiple recent open-market sales totaling 12,372 shares in July–September 2025, which may be perceived negatively by some investors
• Form does not specify a 10b5-1 trading plan adoption date, limiting context about whether sales follow a pre-established plan

Insights

Securities Analyst

TL;DR: Insider plans a modest sale of 3,000 shares; several recent disposals total 12,372 shares over the past three months.

The notice shows a proposed sale executed through a broker with an aggregate market value near $480k. The securities being offered were recently issued as restricted stock by the company in January 2025, which explains the use of Rule 144 to effect resale. The presence of multiple prior sales by the same holder (12,372 shares) is a material disclosure for market transparency but, standing alone, does not quantify impact on trading liquidity or valuation without share count context. This is a routine insider resale filing rather than an operational disclosure.

Corporate Governance Expert

TL;DR: Repeated insider sales are notable for governance observers but the filing records restricted stock origins and required attestation.

The form documents that the shares originated as restricted awards from the issuer, indicating compensatory rather than third-party acquisition. The seller certifies lack of nonpublic adverse information, which is standard. Governance review would note concentrated selling activity by this individual across several months (documented sales in July–September 2025) and consider whether sales align with trading plans or raise signaling questions; however, the form does not include a 10b5-1 plan adoption date or additional context, so no conclusions about intent or policy compliance can be drawn from this filing alone.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	3000	479968.80	137248106	10/01/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/27/2025	Restricted Stock	ISSUER			833	01/27/2025	Not Applicable
Common	01/26/2025	Restricted Stock	ISSUER			2167	01/26/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
SOLOMON MOSHKEVICH 13011 McCallen Pass Building A Suite 100 Austin TX 78753	Common	09/02/2025	3000	499864.50
SOLOMON MOSHKEVICH 13011 McCallen Pass Building A Suite 100 Austin TX 78753	Common	08/14/2025	875	136027.22
SOLOMON MOSHKEVICH 13011 McCallen Pass Building A Suite 100 Austin TX 78753	Common	08/01/2025	3000	398657.40
SOLOMON MOSHKEVICH 13011 McCallen Pass Building A Suite 100 Austin TX 78753	Common	07/28/2025	2206	308417.11
SOLOMON MOSHKEVICH 13011 McCallen Pass Building A Suite 100 Austin TX 78753	Common	07/21/2025	291	40533.39
SOLOMON MOSHKEVICH 13011 McCallen Pass Building A Suite 100 Austin TX 78753	Common	07/01/2025	3000	500304.90

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares of NTRA are being reported for sale in this Form 144?

The notice reports a proposed sale of 3,000 common shares of Natera through Morgan Stanley Smith Barney LLC with an aggregate market value of $479,968.80.

How were the securities being sold acquired?

The securities were acquired as restricted stock from the issuer on 01/26/2025 and 01/27/2025 (2,167 and 833 shares respectively).

Has the seller recently sold other NTRA shares?

Yes. The filing lists open-market sales by the same seller totaling 12,372 shares across July–September 2025 with disclosed gross proceeds for each trade.

Through which broker will the proposed sale be executed?

The broker listed is Morgan Stanley Smith Barney LLC, Executive Financial Services located at 1 New York Plaza, New York, NY.

Does the Form 144 state the seller knows of undisclosed material adverse information?

By signing the notice the person represents that they do not know any material adverse information

Is there information on a Rule 10b5-1 trading plan in this filing?

The form includes a field for plan adoption or instruction date, but this filing does not provide a 10b5-1 plan adoption date